GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer

Phase 1/2 dose-escalation study of a GM-

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

✍ Celestia S. Higano; John M. Corman; David C. Smith; Arthur S. Centeno; Christoph 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

## Abstract ## BACKGROUND This open‐label, multicenter, dose‐escalation study evaluated multiple dose levels of immunotherapy in patients with metastatic hormone‐refractory prostate cancer (HRPC). The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate‐carcinoma cell line